Variety of qualified clients: CDEC talked over the uncertainty in the number of patients with moderately severe to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some sufferers who're labeled as obtaining gentle or moderate illness may have a severe bleeding phenotype, whi